Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Trial Profile

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; K NK002 (Primary) ; Fludarabine; Melphalan
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus First in man; Proof of concept; Therapeutic Use
  • Acronyms NK-REALM
  • Sponsors CytoSen Therapeutics; Kiadis Pharma

Most Recent Events

  • 16 Jun 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
  • 23 Feb 2021 Planned End Date changed from 1 Mar 2023 to 1 Nov 2023.
  • 23 Feb 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top